Alterity Therapeutics Ltd (ATHE)vsEli Lilly and Company (LLY)
ATHE
Alterity Therapeutics Ltd
$4.02
-2.52%
HEALTHCARE · Cap: $88.31M
LLY
Eli Lilly and Company
$1,105.00
+1.80%
HEALTHCARE · Cap: $905.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1088578% more annual revenue ($72.25B vs $6.64M). LLY leads profitability with a 35.0% profit margin vs -219.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).
ATHE
Avoid26
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 74.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -46.4% — below average capital efficiency
Distress zone — elevated risk
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ATHE
The strongest argument for ATHE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 74.6% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ATHE
The primary concerns for ATHE are EPS Growth, Market Cap, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
ATHE profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
ATHE is growing revenue faster at 74.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 26/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alterity Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?